Progyny Inc. (PGNY) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (24% profit margin, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-02, Progyny Inc. (NASDAQ: PGNY) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $28.40 (+1.90% 1D, market cap $2.18B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PGNY ranks #21 in composite RQD confidence.
Within the Health Care sector (Misc Health and Biotechnology Services), PGNY carries a Roarable B+ (78/100 RQD), trailing P/E of 37.2x, gross margin of 23.6%, and ROIC of 16.7%. By comparison, AGL (agilon health inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.44B) and SHC (Sotera Health Company) posts a D+ grade (53/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.34B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).
Per PGNY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001551306), Progyny Inc. generated $1.29B in revenue (+10.4% YoY), $58.5M in net income, and $191.8M in free cash flow against $742.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (24% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 14.9% FCF Margin ($191.8M FCF) & 23.6% Gross Margin
SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)
Macro rate sensitivity & RSI-14 (55.1) create a -5 pt regime headwind
Even with a 78/100 (B+) score, PGNY faces multiple-compression risk if 37.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 21.1% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($26.93) or 200D SMA ($24.38) invalidates the momentum regime and cuts Target Base ($30.96) toward Bear Floor ($23.29).
Progyny Inc. (PGNY) advanced +1.90% to $28.40, trading at 73% of its 52-week range ($16.1 – $33.06). High-quality cash engine (24% profit margin, 17% return on capital) with steady institutional support.
Guidance cut puts Progyny’s recent move in context Progyny (PGNY) reset the conversation for investors after trimming its full year revenue outlook to a range of $1.36b to $1.385b, citing softer utilization patterns than
Progyny has delivered a sharp 56.1% share price gain over the past year, and that kind of run naturally raises a simple question for holders and onlookers alike. Is the current valuation still grounded in what the busine
Progyny cut its 2026 revenue guidance to US$1.36b to US$1.385b after softer than expected fertility benefit utilization that management framed as seasonal rather than structural. The company still points to encouraging e
The Easterly Snow Capital Small Cap Value Fund is a U.S. open-end equity mutual fund managed by Easterly Asset Management, sub-advised by Snow Capital Management. The letter can be downloaded here. The Easterly Snow Smal
PGNY pairs strong profitability and zero debt with a bull flag setup, offering a growth screen candidate with fundamentals and technicals aligned.
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
What a fantastic six months it’s been for Progyny. Shares of the company have skyrocketed 51.1%, hitting $27.77. This performance may have investors wondering how to approach the situation.
Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility careNEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pro
More than 70% of members in the study reported symptom improvement, with the greatest gains among those receiving both personalized coaching and menopause-trained provider careNEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) --
For questions about this article or underlying research, email help@trefis.com.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PGNY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PGNY. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Progyny Inc. (PGNY) ranks #21 by composite RQD confidence (78/100, grade B+) and #248 by equity capitalization ($2.18B). Within this direct 5-issuer industry benchmark cohort, DVA leads on earnings valuation at 11.4x trailing P/E, while DVA leads on capital efficiency and profitability with 29.2% ROIC and — gross margin. PGNY currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PGNY
ACTIVE
Progyny Inc. | B+ | 78/100 | 37.2x | 23.6% | 16.7% | +1.90% | $2.18B | Benchmark Subject |
| AGL agilon health inc. | D- | 37/100 | — | — | -35.0% | -5.56% | $1.44B | /agl-vs-pgny → |
| SHC Sotera Health Company | D+ | 53/100 | 68.5x | 55.5% | 3.1% | +0.27% | $5.34B | /shc-vs-pgny → |
| DVA DaVita Inc. | B+ | 77/100 | 11.4x | — | 29.2% | +5.10% | $12.33B | /dva-vs-pgny → |
| VMD Viemed Healthcare Inc. | B | 75/100 | 24.6x | 57.5% | 13.0% | -0.40% | $379.0M | /vmd-vs-pgny → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Progyny Inc. (PGNY) reported GAAP revenue of $1.29B (+10.4% vs. FY2024 revenue of $1.17B , and +18.4% cumulative change since FY2023) , GAAP net income of $58.5M, operating cash flow of $210.2M, and free cash flow of $191.8M (+10.4% YoY). On the balance sheet, PGNY closed FY2025 with $742.4M in total assets against $0 in total debt (Altman Z-Score: 8.84, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.29B | $58.5M | $210.2M | $191.8M | $742.4M | — |
| FY2024 (FY) | 2024-12-31 | $1.17B | $54.3M | $179.1M | $173.7M | $607.1M | — |
| FY2023 (FY) | 2023-12-31 | $1.09B | $62.0M | $188.8M | $188.8M | — | — |
As of 2026-11-02, Progyny Inc. (NASDAQ: PGNY) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $28.40 (+1.90% 1D, market cap $2.18B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PGNY ranks #21 in composite RQD confidence.
Within the Health Care sector (Misc Health and Biotechnology Services), PGNY carries a Roarable B+ (78/100 RQD), trailing P/E of 37.2x, gross margin of 23.6%, and ROIC of 16.7%. By comparison, AGL (agilon health inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.44B) and SHC (Sotera Health Company) posts a D+ grade (53/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.34B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).
Per PGNY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001551306), Progyny Inc. generated $1.29B in revenue (+10.4% YoY), $58.5M in net income, and $191.8M in free cash flow against $742.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (24% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
PGNY last traded at $28.40 (+1.90% on volume of 657,499 shares), positioning the stock +5.46% above its 50-day simple moving average ($26.93) and +16.49% above its 200-day simple moving average ($24.38). Across its 52-week range of $16.10 to $33.06, PGNY sits at the 72.5% percentile with a 14-day RSI of 55.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.3% ($26.33 to $30.47).
Why PGNY Stock advanced +1.90% Today — RQD Quant Desk Flash. High-quality cash engine (24% profit margin, 17% return on capital) with steady institutional support.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).